Published in Gene Therapy Weekly, August 12th, 2004
IR103 combines the company's patented HIV-1 immunogen with the immunostimulatory oligonucleotide adjuvant Amplivax. Results of two studies were presented at the XV International AIDS Conference in Bangkok, Thailand.
A preclinical study in which mice immunized subcutaneously with IR103 showed significantly enhanced production of a number of key markers of HIV-specific immune responses. These data demonstrate the potential to enhance both cell-mediated and humoral immunity, both of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.